timothy sykes logo
PDSB Jumps As PDS Biotechnology’s Phase 2 Data Impress And Nant Deal Reshapes Outlook Thumbnail
G Google News

PDSB Jumps As PDS Biotechnology’s Phase 2 Data Impress And Nant Deal Reshapes Outlook

TIM SYKES•UPDATED OCT. 11, 2026, 10:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

PDS Biotechnology Corporation stocks have been trading up by 30.39 percent amid heightened optimism over its latest oncology pipeline developments.

What Traders Need To Know

  • Peer‑reviewed Phase 2 VERSATILE‑002 data in JAMA Oncology showed PDS0101 plus pembrolizumab achieved a 36% objective response rate in CPS ≥1 patients and a 39.3‑month median overall survival in HPV16‑positive recurrent/metastatic head and neck cancer, versus a 19% historical response rate for pembrolizumab alone, with a tolerable safety profile.
  • PDS Biotechnology raised about $11.3M in the initial closing of a PIPE financing of up to $22.3M, selling common stock or pre‑funded warrants plus common warrants at roughly $0.28 per unit, extending its cash runway but creating meaningful dilution.
  • The PIPE financing, led by Nant Capital, includes a potential additional ~$11M contingent on submission of a Phase 3 protocol for PDS0301 in metastatic colorectal cancer and will be used in part to repay debt and fund late‑stage development of the IL‑12 immunocytokine program.
  • As part of the Nant‑led deal, Patrick Soon‑Shiong and James Banaag joined PDS Biotechnology’s board of directors, and NantWorks received a one‑year exclusive option to negotiate an exclusive license for HPV immunotherapy PDS0101.
  • A Schedule 13D filing revealed that an investor or group has acquired a significant beneficial ownership stake in PDSB, signaling the presence of an active or potentially activist shareholder.

Candlestick Chart

Weekly Update Oct 05 – Oct 09, 2026: On Sunday, October 11, 2026 PDS Biotechnology Corporation stock [NASDAQ: PDSB] is trending up by 30.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

PDS Biotechnology is a distressed micro-cap immuno-oncology developer with negative equity (stockholders’ equity –$3.6M) and severely negative returns (ROA –136.7%, ROE –544%), underscoring accumulated losses and heavy dilution. Liquidity is strained with a current ratio of 0.6 and quick ratio of 0.5, while working capital is –$5.3M, making the business dependent on continual external financing. Operating income for Q2 2026 was –$6.5M and net income –$9.8M, versus cash of only ~$5.6M, so the $22.3M PIPE is life-support, not growth capital.

Technically, PDSB just staged a sharp rebound: after trading tightly around $1.01–1.06 early in the week, it spiked to a $1.38 high and closed near $1.34, a clear bullish breakout from the $1.05 congestion zone. Intraday 5‑minute candles show strong upside momentum with expanding volume into the close, consistent with news-driven accumulation. The dominant trend has turned up in the near term; $1.05 is now the key actionable support level to trade against for aggressive long entries.

Fundamentally, PDSB’s JAMA Oncology Phase 2 data for PDS0101 (36% ORR, 39.3‑month OS) are compelling versus historical benchmarks and, together with Nant Capital’s PIPE, 13D activity, and Soon‑Shiong’s board role, place it near the upper tier of small-cap immunotherapy optionality despite subscale financing vs. biotech peers. However, leverage, dilution, and negative cash flow keep risk well above sector averages. I view the stock as a speculative, catalyst-driven trade with a 3–6 month upside target of $1.75–2.00, support at $1.05 and resistance near $1.50.

More Breaking News

Quick Financial Overview

PDS Biotechnology Corporation sits at a tricky point where strong clinical data collides with a stretched balance sheet. Phase 2 results for PDS0101 plus pembrolizumab, now published in JAMA Oncology, show an objective response rate well above historical pembrolizumab alone and a median overall survival of 39.3 months in a tough HPV16‑positive head and neck setting. For traders, peer‑reviewed data like this often acts as a de‑risking event on the science side, especially when safety looks comparable to standard care.

On the financial side, the story is far less comfortable. PDSB closed an initial $11.3M PIPE at roughly $0.28 per unit, with another ~$11M contingent on filing a Phase 3 protocol for PDS0301. That low pricing, plus attached warrants, explains why the stock sold off more than 8% on the financing news. Current ratio near 0.6 and quick ratio around 0.5 highlight tight liquidity, while negative book value and a price‑to‑tangible book of about -27.9 show how heavily the market is trading on pipeline optionality rather than assets.

Cash burn remains real. Operating cash flow was about -$2.8M for the quarter ended 2026/06/30, with net income around -$9.8M and interest expense elevated. Ending cash of roughly $5.6M before the PIPE would not support long runway, so the raise was effectively forced. Technically, PDSB’s weekly chart shows a bounce from about $1.01 to $1.34 after the clinical headlines, with intraday action spiking from roughly $1.04 to $1.40 and closing near the high. That pattern—sharp volume‑backed pop off recent lows—often attracts short‑term momentum traders, but dilution and weak fundamentals can cap follow‑through.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”